Administration of Vaginal and Rectal Progesterone During FET Cycles

Administration of Vaginal and Rectal Progesterone During Frozen Embryo Transfer Cycles

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03470610

Enrollment

277

Registered

2018-03-20

Start date

2018-02-01

Completion date

2019-09-01

Last updated

2019-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

Progesterone, HRT, frozen embryo transfer

Brief summary

Observational study of reproductive outcome after frozen embryo transfer in HRT with vaginal and rectal progesterone.

Detailed description

Cohort of patients treated with autologous blastocyst at the Fertility clinic Skive Regional Hospital in HRT cycle. Estradiol stimulation started on second cycle day and on day 12 - 20 vaginal and rectal progesterone is added. Blastocyst transfer on 6th progesterone treatment day. Serum progesterone and hCG measurement 9 or 11 days after embryo transfer.

Interventions

DRUGProgesterone

6 mg estradiol and vaginal and rectal progesterone

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Frozen embryo transfer cycles in HRT cycles

Exclusion criteria

* Donor frozen embryo transfer

Design outcomes

Primary

Measure	Time frame	Description
ongoing pregnancy	4 month	gestational week 12

Secondary

Measure	Time frame	Description
pregnancy rate	4 month	positive hCG
Pregnancy loss	4 month	pregnancy loss before week 7

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026